View Item 

Show simple item record

Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression

dc.contributor.authorLee, Carolynen_US
dc.contributor.authorRamirez, James A.en_US
dc.contributor.authorGuitart, Joanen_US
dc.contributor.authorDiaz, Leslie K.en_US
dc.date.accessioned2010-06-01T21:48:07Z
dc.date.available2010-06-01T21:48:07Z
dc.date.issued2008-11en_US
dc.identifier.citationLee, Carolyn; Ramirez, James A.; Guitart, Joan; Diaz, Leslie K. (2008). "Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression." Journal of Cutaneous Pathology 35(11): 989-994. <http://hdl.handle.net/2027.42/74842>en_US
dc.identifier.issn0303-6987en_US
dc.identifier.issn1600-0560en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74842
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18537861&dopt=citationen_US
dc.format.extent591538 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights© Blackwell Munksgaard 2008en_US
dc.titleExpression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progressionen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationotherDepartment of Dermatology, Stanford University School of Medicine, Stanford, CA, USAen_US
dc.contributor.affiliationotherDepartment of Dermatopathology, St. Joseph Mercy Hospital, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDepartment of Pathology, Northwestern University School of Medicine, Chicago, IL, USAen_US
dc.identifier.pmid18537861en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74842/1/j.1600-0560.2007.00939.x.pdf
dc.identifier.doi10.1111/j.1600-0560.2007.00939.xen_US
dc.identifier.sourceJournal of Cutaneous Pathologyen_US
dc.identifier.citedreferenceWaddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83.en_US
dc.identifier.citedreferenceSmalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 1.en_US
dc.identifier.citedreferenceDannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2: 544.en_US
dc.identifier.citedreferenceOshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803.en_US
dc.identifier.citedreferenceSteinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946.en_US
dc.identifier.citedreferenceKawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409.en_US
dc.identifier.citedreferenceLehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406.en_US
dc.identifier.citedreferenceYamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther 2002; 302: 18.en_US
dc.identifier.citedreferenceKoeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003; 9: 1.en_US
dc.identifier.citedreferenceLefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998; 4: 1053.en_US
dc.identifier.citedreferenceSaez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998; 4: 1058.en_US
dc.identifier.citedreferenceSaez E, Rosenfeld J, Livolsi A, et al. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 2004; 18: 528.en_US
dc.identifier.citedreferenceSarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4: 1046.en_US
dc.identifier.citedreferenceMueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465.en_US
dc.identifier.citedreferenceElstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998; 95: 8806.en_US
dc.identifier.citedreferenceKubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344.en_US
dc.identifier.citedreferenceTontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 1997; 94: 237.en_US
dc.identifier.citedreferenceGoulet AC, Einsphar JG, Alberts DS, et al. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther 2003; 2: 713.en_US
dc.identifier.citedreferenceDenkert C, Kobel M, Berger S, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001; 61: 303.en_US
dc.identifier.citedreferenceKuzbicki L, Sarnecka A, Chwirot BW. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res 2006; 16: 29.en_US
dc.identifier.citedreferenceMossner R, Schulz U, Kruger U, et al. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol 2002; 119: 576.en_US
dc.identifier.citedreferenceNijsten T, Geluyckens E, Colpaert C, Lambert J. Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors. J Cutan Pathol 2005; 32: 340.en_US
dc.identifier.citedreferenceHe G, Muga S, Thuillier P, Lubet RA, Fischer SM. The effect of PPARgamma ligands on UV- or chemically-induced carcinogenesis in mouse skin. Mol Carcinog 2005; 43: 198.en_US
dc.identifier.citedreferencePlacha W, Gil D, Dembinska-Kiec A, Laidler P. The effect of PPARgamma ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res 2003; 13: 447.en_US
dc.identifier.citedreferenceFreudlsperger C, Moll I, Schumacher U, Thies A. Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro. Anticancer Drugs 2006; 17: 325.en_US
dc.identifier.citedreferenceLiu H, Zang C, Fenner MH, Possinger K, Elstner E. PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat 2003; 79: 63.en_US
dc.identifier.citedreferenceMotomura W, Nagamine M, Tanno S, et al. Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells. J Gastroenterol 2004; 39: 461.en_US
dc.identifier.citedreferenceLiu Y, Meng Y, Liu H, et al. Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line a375. Med Oncol 2006; 23: 393.en_US
dc.identifier.citedreferenceMasuda T, Wada K, Nakajima A, et al. Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma. Clin Cancer Res 2005; 11: 4012.en_US
dc.identifier.citedreferenceSchaefer KL, Wada K, Takahashi H, et al. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 2005; 65: 2251.en_US
dc.identifier.citedreferenceDenkins Y, Kempf D, Ferniz M, Nileshwar S, Marchetti D. Role of omega-3 polyunsaturated fatty acids on cyclooxygenase-2 metabolism in brain-metastatic melanoma. J Lipid Res 2005; 46: 1278.en_US
dc.identifier.citedreferenceZhang X, Morham SG, Langenbach R, Young DA. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999; 190: 451.en_US
dc.identifier.citedreferenceSawaoka H, Tsuji S, Tsujii M, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999; 79: 1469.en_US
dc.identifier.citedreferenceWechter WJ, Kantoci D, Murray ED Jr, et al. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res 1997; 57: 4316.en_US
dc.identifier.citedreferencePark BH, Breyer B, He TC. Peroxisome proliferator-activated receptors: roles in tumorigenesis and chemoprevention in human cancer. Curr Opin Oncol 2001; 13: 78.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-0560.2007.00939.x.pdf
Size:
577.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.